Oncology and Hematology - Global Oncology Academy

Episodes 273-288 of 530

Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Global Oncology Academy
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Project Oncology®
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
- Adrienne Waks, MD
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
1.50 credits 10 episodes
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 credits 10 episodes
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
1.25 credits 10 episodes
- Sara Lonardi, MD
- Aparna R. Parikh, MD
- Alan Venook, MD
1.25 credits 10 episodes
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
MinuteCE®
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
MinuteCE®
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Emerging Treatment Approaches for EBC
Emerging Treatment Approaches for EBC
MinuteCE®
Emerging Treatment Approaches for EBC
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
The Evolving Treatment Landscape for MBC: Emerging Therapies
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
Expert Viewpoint: Optimizing Breast Cancer Treatment
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®
Expert Viewpoint: Optimizing Breast Cancer Treatment
1.50 program credits
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Management of HR+, HER2- High-Risk EBC
Management of HR+, HER2- High-Risk EBC
MinuteCE®
Management of HR+, HER2- High-Risk EBC
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
1.25 program credits
- Sara Lonardi, MD
1.25 program credits

18/11